本文已被:浏览 610次 下载 361次
Received:June 24, 2022 Published Online:September 20, 2022
Received:June 24, 2022 Published Online:September 20, 2022
中文摘要: 化疗和内分泌治疗是激素受体(HR)阳性人表皮生长因子受体2 (HER2)阴性乳腺癌全身治疗的重要组成部分,可显著改善患者预后。基于早期的循证医学证据,国内外指南推荐乳腺癌化疗序贯内分泌治疗而非同期。但是,随着对肿瘤生物学行为的理解加深、新药物的研制、治疗方式的更新,同期治疗或许有其独特的治疗优势,也再次引起了学者们的兴趣。本文将从基础研究和临床研究(包括晚期解救治疗、局部晚期新辅助治疗及早期辅助治疗)两方面对HR阳性HER2阴性乳腺癌化疗同期内分泌治疗的最新进展及适用时机进行综述。
Abstract:Chemotherapy and endocrine therapy are important components of systemic therapy for hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer, which can significantly improve the prognosis of patients. Based on early evidence-based medical evidence, domestic and foreign guidelines recommend sequential endocrine therapy rather than concurrent chemotherapy for breast cancer. However, with the deepening of the understanding of tumor biological behavior, the development of new drugs, and the updating of treatment methods, concurrent treatment may have its unique therapeutic advantages, which has once again aroused the interest of scholars. This article will review the latest progress and applicable time of endocrine therapy in the chemotherapy of HR positive HER2 negative breast cancer from two aspects of basic research and clinical research (including late rescue therapy, locally advanced neoadjuvant therapy and early adjuvant therapy).
keywords: Breast cancer Hormone receptor positive Chemotherapy combined with endocrine therapy Human epidermal growth factor receptor 2 Neoadjuvant therapy Aromatase inhibitor
文章编号: 中图分类号:R737.9 文献标志码:A
基金项目:国家自然科学基金(82172683)
引用文本: